Intrinsic hemolytic normocytic anemia: Pathology review

11,797views

Intrinsic hemolytic normocytic anemia: Pathology review

Pediatrics

Pediatrics

Approach to acid-base disorders: Clinical sciences
Approach to metabolic acidosis: Clinical sciences
Approach to metabolic alkalosis: Clinical sciences
Approach to respiratory acidosis: Clinical sciences
Approach to respiratory alkalosis: Clinical sciences
Approach to hypernatremia (pediatrics): Clinical sciences
Approach to hypocalcemia (pediatrics): Clinical sciences
Approach to hypoglycemia (pediatrics): Clinical sciences
Approach to hyponatremia (pediatrics): Clinical sciences
Adrenal insufficiency: Clinical sciences
Syndrome of inappropriate antidiuretic hormone secretion: Clinical sciences
Adnexal torsion: Clinical sciences
Appendicitis: Clinical sciences
Approach to abdominal wall and groin masses: Clinical sciences
Approach to dysmenorrhea: Clinical sciences
Cholecystitis: Clinical sciences
Ectopic pregnancy: Clinical sciences
Henoch-Schonlein purpura: Clinical sciences
Inflammatory bowel disease (Crohn disease): Clinical sciences
Inflammatory bowel disease (ulcerative colitis): Clinical sciences
Intussusception: Clinical sciences
Irritable bowel syndrome: Clinical sciences
Pelvic inflammatory disease: Clinical sciences
Testicular torsion (pediatrics): Clinical sciences
Urinary tract infection (pediatrics): Clinical sciences
Approach to anemia (destruction and sequestration): Clinical sciences
Approach to anemia (underproduction): Clinical sciences
Approach to anemia in the newborn and infant (destruction and blood loss): Clinical sciences
Approach to anemia in the newborn and infant (underproduction): Clinical sciences
Approach to leukemia: Clinical sciences
Iron deficiency and iron deficiency anemia (pediatrics): Clinical sciences
Sickle cell disease: Clinical sciences
Approach to bleeding disorders (platelet dysfunction): Clinical sciences
Approach to bleeding disorders (thrombocytopenia): Clinical sciences
Immune thrombocytopenia: Clinical sciences
Meningitis (pediatrics): Clinical sciences
Sepsis (pediatrics): Clinical sciences
Celiac disease: Clinical sciences
Asthma: Clinical sciences
Bronchiolitis: Clinical sciences
Congestive heart failure: Clinical sciences
COVID-19: Clinical sciences
Croup and epiglottitis: Clinical sciences
Cystic fibrosis and primary ciliary dyskinesia: Clinical sciences
Influenza: Clinical sciences
Pneumonia (pediatrics): Clinical sciences
Tuberculosis (pulmonary): Clinical sciences
Upper respiratory tract infections: Clinical sciences
Clostridioides difficile infection: Clinical sciences
Approach to a fever (over 2 months): Clinical sciences
Acute rheumatic fever and rheumatic heart disease: Clinical sciences
Osteomyelitis (pediatrics): Clinical sciences
Otitis media and externa (pediatrics): Clinical sciences
Pharyngitis, peritonsillar abscess, and retropharyngeal abscess (pediatrics): Clinical sciences
Septic arthritis and transient synovitis (pediatrics): Clinical sciences
Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical sciences
Tuberculosis (extrapulmonary and latent): Clinical sciences
Approach to bacterial causes of fever and rash (pediatrics): Clinical sciences
Acute group A streptococcal infections and sequelae (pediatrics): Clinical sciences
Approach to congenital infections: Clinical sciences
Juvenile idiopathic arthritis: Clinical sciences
Kawasaki disease: Clinical sciences
Lyme disease: Clinical sciences
Periorbital and orbital cellulitis (pediatrics): Clinical sciences
Toxic shock syndrome: Clinical sciences
Staphylococcal scalded skin syndrome and impetigo: Clinical sciences
Approach to a murmur (pediatrics): Clinical sciences
Approach to congenital heart diseases (acyanotic): Clinical sciences
Approach to congenital heart diseases (cyanotic): Clinical sciences
Hypertrophic cardiomyopathy: Clinical sciences
Approach to hepatic masses: Clinical sciences
Hepatitis A and E: Clinical sciences
Hepatitis B: Clinical sciences
Hepatitis C: Clinical sciences
Approach to a limp (pediatrics): Clinical sciences
Approach to a suspected bone tumor (pediatrics): Clinical sciences
Developmental dysplasia of the hip: Clinical sciences
Legg-Calve-Perthes disease and slipped capital femoral epiphysis: Clinical sciences
Approach to peripheral lymphadenopathy (pediatrics): Clinical sciences
Approach to a red eye: Clinical sciences
Approach to vomiting (newborn and infant): Clinical sciences
Acetaminophen (Paracetamol) toxicity: Clinical sciences
Approach to recreational substance exposure (pediatrics): Clinical sciences
Diabetes mellitus (pediatrics): Clinical sciences
Large bowel obstruction: Clinical sciences
Pyloric stenosis: Clinical sciences
Small bowel obstruction: Clinical sciences
Approach to a fever (0-60 days): Clinical sciences
Approach to jaundice (newborn and infant): Clinical sciences
Non-accidental trauma and neglect (pediatrics): Clinical sciences
Necrotizing enterocolitis: Clinical sciences
Neonatal respiratory distress syndrome: Clinical sciences
Approach to respiratory distress (newborn): Clinical sciences
Approach to cyanosis (newborn): Clinical sciences
Approach to shock (pediatrics): Clinical sciences
Approach to lower airway obstruction (pediatrics): Clinical sciences
Approach to upper airway obstruction (pediatrics): Clinical sciences
Anaphylaxis: Clinical sciences
Foreign body aspiration and ingestion (pediatrics): Clinical sciences
Approach to a first unprovoked seizure (pediatrics): Clinical sciences
Febrile seizure (pediatrics): Clinical sciences
Approach to bradycardia: Clinical sciences
Approach to tachycardia: Clinical sciences
Brief, resolved, unexplained event (BRUE): Clinical sciences
Approach to hematochezia (pediatrics): Clinical sciences
Burns: Clinical sciences
Neurogenic shock: Clinical sciences
Approach to delayed puberty: Clinical sciences
Approach to feeding and eating disorders: Clinical sciences
Approach to neurodevelopmental disorders: Clinical sciences
Approach to precocious puberty: Clinical sciences
Approach to short stature: Clinical sciences
Autism spectrum disorder: Clinical sciences
Approach to a child with Down syndrome (trisomy 21): Clinical sciences
Dyslipidemia: Clinical sciences
Essential hypertension: Clinical sciences
Developmental milestones (newborn and infant): Clinical sciences
Developmental milestones (toddler): Clinical sciences
Developmental milestones (childhood): Clinical sciences
Approach to a rash in the well newborn and infant: Clinical sciences
Immunizations (pediatrics): Clinical sciences
Well-child visit (adolescent): Clinical sciences
Well-child visit (newborn and infant): Clinical sciences
Well-child visit (toddler and child): Clinical sciences
Well-patient care (GYN): Clinical sciences
Sports physical (pediatrics): Clinical sciences
Antidiuretic hormone
Body fluid compartments
Movement of water between body compartments
Sodium homeostasis
Acid-base disturbances: Pathology review
Diabetes insipidus and SIADH: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Acyanotic congenital heart defects: Pathology review
Adrenal masses: Pathology review
Bacterial and viral skin infections: Pathology review
Bone tumors: Pathology review
Coagulation disorders: Pathology review
Congenital neurological disorders: Pathology review
Cyanotic congenital heart defects: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Headaches: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Leukemias: Pathology review
Lymphomas: Pathology review
Macrocytic anemia: Pathology review
Microcytic anemia: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Nephritic syndromes: Pathology review
Nephrotic syndromes: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Pediatric brain tumors: Pathology review
Pediatric musculoskeletal disorders: Pathology review
Platelet disorders: Pathology review
Renal and urinary tract masses: Pathology review
Seizures: Pathology review
Viral exanthems of childhood: Pathology review
Adrenal insufficiency: Pathology review
Central nervous system infections: Pathology review
Childhood and early-onset psychological disorders: Pathology review
Congenital gastrointestinal disorders: Pathology review
Diabetes mellitus: Pathology review
Environmental and chemical toxicities: Pathology review
Gastrointestinal bleeding: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Inflammatory bowel disease: Pathology review
Medication overdoses and toxicities: Pathology review
Obstructive lung diseases: Pathology review
Pneumonia: Pathology review
Psychiatric emergencies: Pathology review
Shock: Pathology review
Supraventricular arrhythmias: Pathology review
Traumatic brain injury: Pathology review
Ventricular arrhythmias: Pathology review
Congenital TORCH infections: Pathology review
Jaundice: Pathology review
Respiratory distress syndrome: Pathology review
Autosomal trisomies: Pathology review
Cystic fibrosis: Pathology review
Disorders of sex chromosomes: Pathology review
HIV and AIDS: Pathology review
Miscellaneous genetic disorders: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Anxiety disorders, phobias and stress-related disorders: Pathology Review
Developmental and learning disorders: Pathology review
Eating disorders: Pathology review
Mood disorders: Pathology review
Breastfeeding
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Drug-receptor interactions
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug metabolism
Androgens and antiandrogens
Estrogens and antiestrogens
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Antihistamines for allergies
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Glucocorticoids
Azoles
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants

Transcript

Watch video only

On the hematology ward, there’s a mother with her daughter, Kyra, a five -year old that has developed jaundice and complains of easy fatigability. She is an adopted child with an unknown family history. Clinical examination reveals a palpable spleen. Next to her, there’s a 35-year-old person of African descent, called Darnell, who started trimethoprim-sulfamethoxazole for treatment of acute prostatitis a few weeks ago. Recently, he developed jaundice, dark urine, back pain and fatigue. There’s also a father who brought Billy, his 13-year-old son, to the emergency department because of a painful and prolonged erection. CBC is ordered for all of them and it shows low hemoglobin with normal MCV and reticulocyte count index over 2%. They also have increased LDH. Now, Kyra also has an increased MCHC and spherocytes on peripheral blood smear, while Billy has sickled cells.

Although their symptoms are very different, they all suffer from anemia, which is defined as lower than average levels of hemoglobin, typically below 13.5 g/dL in adult men and below 12.0 g/dL in adult women.This level varies based on the age for children. Now, anemias can be broadly grouped into 3 categories based on mean corpuscular volume, or MCV, which reflects the volume of a red blood cell. So microcytic anemia is where the MCV is lower than 80 fL, normocytic, with an MCV between 80 and 100 fL, and macrocytic, with an MCV larger than 100 fL. Normocytic anemias can be further classified as hemolytic when there’s increased destruction of RBCs, or hemolysis, and non-hemolytic when there’s decreased production of RBCs from the bone marrow. When there’s hemolysis, the bone marrow revs up and starts pumping out immature RBCs called reticulocytes, but when there’s a bone marrow problem reticulocyte count is low. So for your exams, it’s important to know that in hemolytic anemias there’s an increased reticulocyte production index of over 2%, while in non-hemolytic anemias it’s lower than 2%.

Alright, now hemolytic anemias can be classified as intrinsic and extrinsic hemolytic anemias. In intrinsic hemolytic anemias, the RBCs are destroyed due to RBC membrane defects, like in hereditary spherocytosis and paroxysmal nocturnal hemoglobinuria, or PNH; enzyme deficiencies, like in glucose 6 phosphate, or G6PD, deficiency and pyruvate kinase deficiency; and hemoglobin abnormalities, like in sickle cell anemia. Now, in extrinsic hemolytic anemias, the RBCs are normal but are later destroyed via extrinsic mechanisms such as autoantibodies directed against RBCs. In this video, let’s focus on intrinsic hemolytic anemias.

Now, we can also divide intrinsic hemolysis into intravascular, meaning RBCs are destroyed within the vasculature, or extravascular, meaning that they are removed by macrophages in the spleen and liver. Hereditary spherocytosis and pyruvate kinase deficiency cause extravascular hemolysis, PNH causes intravascular, while G6PD deficiency and sickle cell anemia can cause both intravascular and extravascular hemolysis. There are findings that can help identify the type of hemolysis. In intravascular hemolysis, hemoglobin that is released inside the vessels gets bound by a protein called haptoglobin and because they’re removed together, haptoglobin decreases. Also, when haptoglobin gets overwhelmed, the rest of hemoglobin goes via the blood through the kidneys and into the urine resulting in hemoglobinuria. Now, when hemoglobin is inside the renal tubules, the cells lining the renal tubules reabsorb hemoglobin. The heme component of hemoglobin contains iron which is stored as hemosiderin in tubular cells and after a few days, when tubular cells slough into urine, there’s hemosiderinuria. Hemoglobinuria and hemosiderinuria can damage the kidneys causing back pain. Okay, now in extravascular hemolysis, RBCs are destroyed outside the vessels and so, haptoglobin is normal and there’s no hemoglobin or hemosiderin in the urine. RBCs are usually destroyed in the spleen causing splenomegaly or the liver causing hepatomegaly.

Alright, now whenever there’s RBC lysis, an intracellular enzyme called lactate dehydrogenase, or LDH, spills out directly into the plasma and builds up in the blood. Hemoglobin also spills out of the cell and breaks up into globin and heme. Heme is converted into unconjugated, or indirect, bilirubin which is then taken up by the liver cells and eventually secreted out with bile. If all of a sudden, your body starts breaking down more RBCs than the liver cells can handle, the excess bilirubin stays in the blood and cause jaundice where the bilirubin deposits in the skin and the eyes, causing them to turn yellow. Also, when there’s too much bilirubin in the bile, it can form pigmented gallstones. Some of the bilirubin is converted to urobilin which is what gives urine that yellow color, but if there’s too much of it, the urine becomes a much darker, tea-like color.

Okay, so first let’s look at intrinsic hemolytic anemias caused by RBC membrane abnormalities which include hereditary spherocytosis and PNH. Hereditary spherocytosis is an autosomal dominant disorder characterized by defects in the spectrin and ankyrin proteins found in the RBC membrane. This results in abnormally shaped RBC that are more spherical instead of the normal flexible biconcave disks. The spherocytes get trapped and destroyed in the spleen resulting in chronic, mild extravascular hemolysis.

Next is paroxysmal nocturnal hemoglobinuria, PNH, a genetic disorder caused by a mutated PIG-A gene in myeloid stem cells. This gene encodes for a protein called phosphatidyl inositol glycan A that is needed to synthesize another protein called GPI anchor. GPI anchor is found in the membrane of all types of blood cells and serves to anchor proteins like decay accelerating factor, or DAF, also known as CD55, and CD59, to the cell membrane. These proteins normally inactivate the complement and so they protect the cells from complement lysis. So, a high yield concept for your exams is that in PNH, the complement stays activated and causes intravascular hemolysis.Another important fact to remember is that since PNH affects stem cells, it can cause aplastic anemia or pancytopenia. It also affects other blood cells like platelets and can cause formation of blood clots and thrombosis. So, an important clue to help you identify this disorder is that the patient can have thrombosis, hemolytic anemia, and reduced blood cell counts. In some cases, it could even lead to leukemia!

Alright, moving onto intrinsic hemolytic anemia due to enzyme defects. The most common is G6PD deficiency, an X-linked recessive disorder characterized by decreased levels of an enzyme called G6PD. It almost exclusively manifests as a disease in males, while females are carriers and is more common in individuals of African, Mediterranean and Asian descent. G6PD deficiency leads to hemolysis by making RBCs susceptible to damage caused by free radicals. But first things first. Free radicals, which are products of metabolism, can destroy RBCs but normally, a molecule in our body called glutathione neutralizes them. Glutathione needs to be in the reduced state where it can donate protons and electrons to the H2O2 and convert them into water. This causes glutathione to become oxidized, so before it can get back to work, an enzyme called glutathione reductase uses NADPH to reduce the oxidized glutathione, and NADPH becomes NADP+. So to replenish the supply of NADPH, we have G6PD, which reduces NADP+ back to NADPH. Okay, so in G6PD deficiency, low levels of G6PD causes low levels of NADPH, leading to low levels of reduced glutathione and increased susceptibility to hemolytic episodes caused by free radicals. Hemolysis usually happens in response to certain triggers like infections, metabolic acidosis, and foods and drinks like fava beans, soy products, red wine, and others. A high yield fact is that certain medications also act as oxidant stressors like the antimalarials, primaquine and chloroquine, painkillers like aspirin and ibuprofen, quinidine that is used to treat arrhythmias, and other medications that contain sulfonamide like the antibiotic trimethoprim-sulfamethoxazole. An interesting fact is that G6PD deficiency protects against Plasmodium falciparum that causes malaria since it makes the parasite-infected RBC more susceptible to oxidants, which will also kill the malaria parasites.

Another less common enzyme defect is pyruvate kinase deficiency. This is an autosomal recessive disorder characterized by decreased levels of an enzyme called pyruvate kinase. Pyruvate kinase is an enzyme involved in glycolysis, which is when glucose gets processed in order to generate energy in the form of adenosine triphosphate, or ATP. So, deficiency of this enzyme makes RBCs deficient in ATP Without ATP, sodium potassium ATPase pumps stop working. And because the cell membrane is more permeable to potassium than sodium, potassium leaks out. This makes the intracellular fluid hypotonic, so water moves out of the cell and the cell shrinks. These dehydrated RBCs can form tiny, uniform projections, turning into echinocytes or Burr cells. And these abnormally shaped RBCs get trapped and destroyed in the spleen, resulting in extravascular hemolysis. Now, another high-yield fact is that pyruvate kinase-deficient RBCs show enhanced oxygen delivery. That’s because the block in glycolysis results in the buildup of a metabolic intermediate called 2,3-bisphosphoglycerate or 2,3-BPG for short. 2,3-BPG has a strong affinity for hemoglobin, so within tissues, it competes with oxygen, thus reducing oxygen-hemoglobin affinity, allowing more oxygen to be released from hemoglobin to the tissues.

Okay, let’s move on to hemolytic anemia due to hemoglobin defects. The most common ones are sickle cell disease, also called sickle cell anemia, and hemoglobin C or HbC disease . These are autosomal recessive disorders caused by mutated genes that encode for abnormal adult hemoglobin called hemoglobin S for sickle, or HbS, and hemoglobin C or HbC. There’s substitution of glutamic acid in the sixth position of the beta globin chain, with valine in the case of HbS and lysine in the case of HbC. A mutation in both copies of the gene is needed to get the disease. If the person has just one copy of the mutation and one normal hemoglobin A gene, or HbA for short, then they have an HbS or HbC trait and they’re said to be a carrier. Some individuals have HbSC disease, meaning that they have one of each mutant gene. An important fact to remember is that, like G6PD deficiency carriers, sickle cell and HbC carriers are also protected against malaria, probably because infected RBCs get removed by the spleen. Now in individuals with sickle cell disease, when there’s acidosis, hypoxia, or dehydration, HbS changes its shape, and aggregates with other HbS proteins to form long chains that distort the RBC into a crescent shape, that looks like a sickle. In individuals with HbC disease, HbC is less soluble, so it aggregates into crystals, which build up in red blood cells, making them more rigid. And since there’s less soluble hemoglobin, there’s a relative membrane excess, so red blood cells start resembling a shooting target with a bullseye, with a dark center of hemoglobin, a ring of pallor and an outer band of hemoglobin.

In both cases, this leads to both intravascular and extravascular hemolysis, resulting in increased RBC breakdown, causing jaundice and gallstones, as well as anemia. There’s also increased compensatory erythropoiesis in the bone marrow, leading to new bone formation, and extramedullary hematopoiesis leading to hepatomegaly. In the case of Sickling, there’s also vaso-occlusion, where RBCs get stuck in capillaries, and that leads to tissue ischemia and pain. Often times it’s an emergency, called sickle cell crisis or vaso-occlusive crisis.

Alright, now whatever the cause of hemolytic anemia, all of them can present with symptoms of anemia like fatigue, pallor and shortness of breath, and symptoms of hemolysis like jaundice, dark, tea-colored urine, and back pain due to kidney damage.

Each of these diseases also have specific symptoms that’s special to them and these will help you identify them. In hereditary spherocytosis, because hemolysis is extravascular and occurs in spleen, there’s often splenomegaly. For the exams, remember that individuals with hereditary spherocytosis have chronic hemolysis since birth and thus, they can develop bilirubin stones and cholelithiasis at an early age. Another important fact to remember is that anemia is usually mild but can be severe if there’s folate deficiency or aplastic crisis due to parvovirus B19 infection. In this case, reticulocyte count will be low.

Sources

  1. "Kaplan USMLE Step 2 CK Lecture Notes Internal Medicine" Kaplan Medical (2017)
  2. "Robbins Basic Pathology" Elsevier (2017)
  3. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  4. "Hereditary Spherocytosis - Diagnosis, Surgical Treatment and Outcomes. A Literature Review" Chirurgia (2017)
  5. "Old and new insights into the diagnosis of hereditary spherocytosis" Annals of Translational Medicine (2018)
  6. "Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review" European Journal of Haematology (2015)
  7. "Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel" European Journal of Haematology (2018)
  8. "Glucose-6-Phosphate Dehydrogenase Deficiency" Hematology/Oncology Clinics of North America (2016)
  9. "Sickle cell disease: a review. Immunohematology" Roseff SD (2009)
  10. "Management of Sickle Cell Disease: A Review for Physician Education in Nigeria (Sub-Saharan Africa)" Anemia (2015)
  11. "Diagnostic approach to hemolytic anemias in the adult" Revista Brasileira de Hematologia e Hemoterapia (2015)